Beyond the paradigm that T lymphocytes exert strict control over them, B lymphocytes have recently been assigned numerous functions. 1 Therefore, they are not confined anymore to antibody production. Rather, evidence accumulates that they govern immune responses to self and non-self-antigen through antibody-dependent as well as antibody-independent mechanisms.
An inference from such a sudden awareness is that systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and primary Sjo¨gren's syndrome (SS), long viewed as T cell-driven conditions, are being re-examined from the outset. Thus, this review ventures into the area of the relationships between autoimmune processes and B lymphocytes.
The evidence that B cells are the culprits in SLE, RA and primary SS may be listed under three headings, following recent major breakthroughs in their study. The first is the demonstration that the CD5 molecule acts as a regulator for their activities; the second, the dissection of B-lymphocyte subsets; and the third, the report of two supplemental tumournecrosis factor (TNF) family members. One is referred to as BAFF, for B cell-activating factor of the TNF family, and the other as APRIL, for a proliferation-inducing ligand. No doubt, developing insights into B lymphocyte commitment in nonorgan-specific autoimmune diseases should bring about new therapeutic approaches.
The CD5 control of B lymphocytes
A T cell marker has been found on the B cells from patients with chronic lymphocytic leukaemia, and subsequently identified as CD5. The B-cell populations were divided accordingly, into a major CD5-negative B2 subpopulation, and a minor CD5-positive B1 subpopulation. Not only do the B1 cells accumulate in leukaemia, but they also produce multiple antibodies directed against, among other targets, auto-antigens.
The membrane exposure of CD5 is tightly regulated, and encoded by an 11-exon gene. Upstream of its noncoding region, an endoretrovirus has been uncovered in humans, but not in mice. 2 This disparity reflects that it had been integrated at a time interval between the divergence of New World from Old World monkeys, and that of humans from monkeys. The alternate exon 1 was designated E1B, and the conventional one renamed E1A. Intriguingly, the E1B-CD5 transcripts, which have never been detected in T lymphocytes, are specific for B lymphocytes. In these cells, should E1A be picked up, the first adenosine-thymosine-guanosine (ATG) (setting the synthesis off) is located in this exon 1, and the full-length CD5 calculated to be 67kD. Should it be E1B, the splicing out of E1A shifts the first ATG available down to exon 3, and diminishes the truncated CD5 to 52kD.
Moreover, in contrast to full length CD5, and due to the lack of a leader peptide, truncated CD5 cannot be translocated to the cell surface. One step further, the overlay of red-fluorescent full length protein and green-fluorescent truncated protein, seen yellow in E1A-cd5 and E1B-cd5 cDNA double-transfected cells, suggests that the full length product is prevented by its truncated counterpart from reaching the membrane. 3 This choice precludes the SH2-containing phosphatase (SHP)-1-related B cell antigen receptor (BCR) signal inhibiting effects of CD5. Noteworthy is that bringing the recombination-activating geneencoded enzymes into play is associated with the presence of CD5. In other words, CD5 favours rearrangement of V, D and J segments for the BCR heavy and light chains, avoiding apoptosis of B cells, yet maintaining tolerance to the self. 4 In summary, CD5 contributes to the pathogenesis of nonorgan-specific autoimmune diseases. It behaves as a regulator for autoreactive B lymphocytes. Methylation, one way to silence a gene, determines which exon 1 is transcribed. Full length variants transport SHP-1 to the membrane, increase the concentration of this phosphatase in the vicinity of the BCR, and make autoreactive B cells anergic. Conversely, when truncated variants are synthesized, SHP-1 is left out. In that case, the unrestrained BCR-mediated signals allow expansion of B lymphocytes, secretion of auto-antibodies, and appearance of nonorgan-specific autoimmune diseases. Relative to normal B cells, DNA methylation is defective in SLE B cells, which releases E1B-CD5 for transcription. Given that interleukin (IL)-6 encourages this option by restricting methylation, targeting it could modulate B cell autoreactivity in SLE.
Various subsets of B lymphocytes
B cells may be classified according to four criteria: the expression of CD5, the developmental stages, the phenotype within the germinal centres, and the parts they have been cast for in the immune response.
The presence of CD5 is a hallmark for the B1 cells, but this subpopulation consists of two subsubpopulations. 5 The B1(a) lymphocytes harbour CD5, whereas the B1(b) lymphocytes do not, but share all other attributes of B1 cells. These include the low density of CD45RA and the antibody multispecificity.
To unravel the liability of the different B-lymphocyte subsets for nonorgan-specific autoimmune diseases, a fruitful approach has been to trace their ontogeny. Mature cells settle down in the secondary lymphoid organs. Throughout their peripheral maturation, they progress along sequential stages. 6 They first constitute transitional B lymphocytes. Once their antigen is encountered, the late B cells access the follicles and initiate germinal centres. Alternatively, they move to the marginal zone, which has spawned a flurry of data over the past few years. 7 In particular, based on their propensity to be activated, preventing autoreactive B cells from colonizing this area is essential. However, marginal zone and transitional B cells are present as aggregates, instead of genuine germinal centres, 8 in exocrine glands of patients with SS and synovial membranes of those with RA. There, in addition to delivering tonic signals to keep the cells alive, the toll-like receptors confer the B lymphocytes with a marginal zone-like phenotype. 9 Then, the relative expression of IgD and CD38 distributes mature B lymphocytes 10 into subsets from Bm1 to Bm5. It is interesting that, compared with SLE and RA, this blood B-cell subset profile is diagnostic for primary SS.
The fourth criterion for B cell classification relies on the functions. Above all, regulatory B lymphocytes have recently been described in humans. They control the production of IL-12 by dendritic cells, 11 and ironically engage regulatory T lymphocytes through IL-10 synthesis. 12 These B cells exhibit high quantities of CD5, and indeed the latter protein promotes the production of IL-10 via at least two transcription factors. 13 In summary, disturbances of B lymphocyte subsets contribute also to the pathogenesis of nonorgan-specific autoimmune diseases. For example, the regulatory B lymphocyte population has been shown to be functionally impaired in SLE patients, 14 but neither in RA, nor in primary SS (our unpublished results).
The late news on BAFF and APRIL
Substantial progress in the understanding of SLE and allied disorders occurred with the discovery that BAFF and APRIL were involved in autoimmunity. 15 Transgenic mice that over-express BAFF develop an SLE-like setting and, as they age, an SS-like setting. In fact, BAFF activates B cells, substitutes for CD40 in immunoglobulin class switch, serves as a dominant survival factor to rescue unwanted autoreactive B lymphocytes, and infiltrates lymphoid tissues with the help of T lymphocytes via TNF. But crossing BAFF-transgenic with TNF-knockout mice does not protect their progeny from B cell infiltration, which suggests that BAFF can do the job on its own.
Not surprisingly, a proportion of patients with SLE, RA or primary SS have large amounts of BAFF and APRIL in their serum. At best, the correlation remains modest between disease activity and concentrations of BAFF, and between concentrations of BAFF and the levels of heterotrimers of BAFF and APRIL in SLE. The questions arise why these vary between patients with the same disease using one enzyme-linked immunosorbent assay (ELISA), and for the same patient, using different ELISAs. Given that the most tenable explanation is that none of the assays yields reliable measurements, we have set up an in-house ELISA, useful to monitor the patients under treatment. 16 Now, to the issue of why, in nonorgan-specific autoimmune diseases, BAFF is excessive. To address this, we have dissected the human 6-exon gene for BAFF. The traditional pair of primers provides messenger RNAs (mRNAs) for the conventional BAFF, a longer form, which is 'BAFF, and a shorter form, which is ÁBAFF. A newly designed pair of primers unmasked an extra 471bp band similar to the BAFF mRNA, but without an exon4-encoded 114-bp sequence. 17 This new short transcript was termed Á4BAFF, and the known short transcript Á3BAFF. These appeared to go back and forth from the nucleus to the cytoplasm, and from the cytoplasm to the nucleus, suggesting that Á4BAFF might act as a transcription factor. Even worse, the truncated protein was shown to be the transcription factor of the full length protein.
In summary, this system contributes as well to the pathogenesis of nonorgan-specific autoimmune diseases. There was indeed too much Á4BAFF mRNA in epithelial cells from primary SS patients compared with normal controls, and in synovial cells from RA patients compared with disease controls (submitted).
To conclude, there is a revival of interest in B lymphocytes as the cause of nonorgan-specific autoimmune diseases. Despite a number of caveats, new therapeutic avenues have thus been opened through the use of B cell-depleting monoclonal antibodies, particularly in RA, 18 of monoclonal antibodies directed to the receptors for IL-6, particularly in SLE, 19 and of BAFF antagonists, be they monoclonal antibodies or decoy receptors, particularly in primary SS. 20 All these agents hold promise in the treatments of nonorgan-specific autoimmune diseases.
